Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis
Described herein is a method of induced cell death via ferroptosis by nanoparticle ingestion. Moreover, the present disclosure describes the administration of high concentrations of ultrasmall nanoparticles at multiple times over the course of treatment in combination with a nutrient-depleted environment, thereby modulating cellular metabolic pathways to induce cell death by the mechanism ferroptosis. Ferroptosis involves iron, reactive oxygen species, and a synchronous mode of cell death execution.
1. A method of treatment of a subject, the method comprising:
administering nanoparticles at an administered concentration greater than 1 μM to diseased tissue to induce ferroptosis of the diseased tissue, characterized by an increased intracellular concentration of iron in the diseased tissue as compared to non-treated cells,
wherein the administered nanoparticles have an average diameter no greater than 15 nm, and
wherein the administered nanoparticles do not have a drug attached thereto.
2. The method of claim 1 , wherein the tissue is amino acid deprived.
3. A method of combinational treatment of a subject, the method comprising:
depriving a diseased tissue of hormones; and
administering nanoparticles at an administered concentration greater than 1 μM to diseased tissue to induce ferroptosis of the diseased tissue, characterized by an increased intracellular concentration of iron in the diseased tissue as compared to non-treated cells,
wherein the administered nanoparticles have an average diameter no greater than 15 nm, and
wherein the administered nanoparticles do not have a drug attached thereto.
4. The method of claim 3 , wherein the tissue is deprived of hormones via castration.
5. The method of claim 3 , wherein the tissue is amino acid deprived.
6. The method of claim 1 , wherein the tissue comprises tumor tissue, and wherein the tumor tissue is selected from the group consisting of renal, prostate, melanoma, pancreatic, lung, fibrosarcoma, breast, brain, ovarian, and colon tumor tissue.
7. The method of claim 6 , wherein the tumor pancreatic tissue comprises BxPC3 cells.
8. The method of claim 6 , wherein the tumor lung tissue comprises H1650 cells.
9. The method of claim 1 , wherein the nanoparticles have an average diameter no greater than 10 nm.
10. The method of claim 1 , wherein the nanoparticles have an average diameter from about 5 nm to about 7 nm.
11. The method of claim 1 , wherein the nanoparticles comprise from 1 to 20 targeting moieties, wherein the targeting moieties bind to receptors on cells.
12. The method of claim 1 , wherein the nanoparticles comprise from 1 to 20 targeting moieties, wherein the 1 to 20 targeting moieties comprises alpha-melanocyte-stimulating hormone (αMSH).
13. The method of claim 1 , wherein the nanoparticles comprise a targeting moiety.
14. The method of claim 1 , wherein the nanoparticles are administered multiple times over the course of treatment.
15. The method of claim 1 , further comprising administering the nanoparticles every 3 or 4 days over the course of treatment.
16. The method of claim 1 , wherein the treatment combines with native immunomodulation properties of the administered nanoparticles to increase the therapeutic potential of the nanoparticles in cancer treatment and/or tissue repair processes.
17. The method of claim 1 , wherein the tissue comprises nutrient-deprived tissue or tumor tissue.
18. The method of claim 1 , wherein the increased intracellular concentration of iron is 8.3 parts per billion (ppb) or higher.
19. The method of claim 1 , wherein the increased intracellular concentration of iron is 144.7 parts per billion (ppb) or higher.
20. The method of claim 1 , wherein the increased intracellular concentration of iron is 2.58 μM or higher.